Paper Details
- Home
- Paper Details
A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients.
Author: QianYu, TengYue, YuanYuan, ZhangLili, ZhangZhe
Original Abstract of the Article :
BACKGROUND: This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer (BC). METHODS: This retrospective study examined 45 patients diagnosed with advanced HER-...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350665/
データ提供：米国国立医学図書館（NLM）
Capecitabine and Lobaplatin: A Treatment for HER-2 Negative Breast Cancer
This retrospective study investigates the efficacy and tolerability of capecitabine and lobaplatin combination therapy in patients with advanced HER-2 negative breast cancer. The authors analyzed data from 45 patients who received this combination therapy, evaluating their response rates, disease control rates, and side effects. The study found that capecitabine and lobaplatin were effective in controlling the disease in a significant proportion of patients, with a favorable safety profile. This research provides valuable insights into the potential of this combination therapy for treating advanced HER-2 negative breast cancer.
Capecitabine and Lobaplatin: A Promising Combination for Breast Cancer Treatment
This retrospective study suggests that capecitabine and lobaplatin combination therapy may be a promising treatment option for patients with advanced HER-2 negative breast cancer. The research highlights the effectiveness of this combination in controlling disease progression and its generally favorable safety profile. This information can guide clinicians in making informed decisions about treatment strategies for this type of breast cancer.
Breast Cancer Treatment: Navigating the Path to Recovery
This study offers valuable insights into the treatment landscape for advanced HER-2 negative breast cancer. The research suggests that capecitabine and lobaplatin combination therapy may be a viable option for managing this type of breast cancer, offering hope and potential for recovery to patients facing a challenging diagnosis. It's like a camel caravan, traversing a vast and challenging desert, equipped with its own arsenal of effective treatments to navigate the journey towards recovery.
Dr.Camel's Conclusion
This retrospective study provides encouraging data on the efficacy and tolerability of capecitabine and lobaplatin combination therapy in patients with advanced HER-2 negative breast cancer. The research highlights the potential of this combination for managing disease progression and suggests that it can be a valuable tool for clinicians in their fight against this challenging form of breast cancer.
Date :
- Date Completed n.d.
- Date Revised 2022-09-02
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.